Was für den hausärztlichen Bereich wichtig ist

Die neue S3-Leitlinie soll die adäquate Versorgung von Menschen mit Typ-1-Diabetes sicher stellen und ihre Lebensquallität verbessern. Aufbau und Struktur der alten S3-Leitlinie wurden beibehalten, der Inhalt wurde komplett überarbeitet und unter Einbeziehung neuester wissenschaftlicher Erkenntnisse und klinischer Erfahrungen aktualisiert.

• Literatur

• 1 Deutsche Diabetes Gesellschaft (DDG) S3-Leitlinie Therapie des Typ-1-Diabetes, 2. Auflage, 2018; www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/2018/S3-LL-Therapie-Typ-1-Diabetes-Auflage-2-Langfassung-09042018.pdf (letzter Zugriff: 28.11.2018)
• 2 Blanco M, Hernández MT, Strauss KW. et al Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes.. Diabetes Metab 2013; 39: 445-453 doi: 10.1016/j.diabet.2013.05.006.
• 3 Grassi G, Scuntero P, Trepiccioni R. et al Optimizing insulin injection technique and its effect on blood glucose control.. J Clin Translat Endocrinol 2014; 1: 145-150 doi: 10.1016/j.jcte.2014.07.006
• 4 Famulla S, Hovelmann U, Fischer A. et al Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control.. Diabetes Care 2016; 39: 1486-1492 doi: 10.2337/dc16-0610
• 5 [No authors listed] Standards of medical care in diabetes – 2017: summary of revsions. Diabetes Care 2017; 40 (Suppl. 01) S4-S5 doi: 10.2337/dc17-S003
• 6 Canadian Diabetes Association. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada; 2013 http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf (letzter Zugriff: 28.11.2018)
• 7 Bergenstal R, Pearson J, Cembrowski GS. et. al Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy.. Diabetes Educ 2000; 26: 981-989 doi: 10.1177/014572170002600610
• 8 Bolinder J, Antuna R, Geelhoed-Duijvestijn P. et al Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.. Lancet 2016; 388: 2254-2263 doi: 10.1016/S0140-6736(16)31535-5
• 9 Battelino T, Conget I, Olsen B. et al The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.. Diabetologia 2012; 55: 3155-3162 doi: 10.1007/s00125-012-2708-9
• 10 Battelino T, Phillip M, Bratina N. et al Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes.. Diabetes Care 2011; 34: 795-800 doi: 10.2337/dc10-1989
• 11 Beck RW, Riddlesworth T, Ruedy K. et al Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial.. JAMA 2017; 317: 371-378 doi: 10.1001/jama.2016.19975
• 12 Langeland LBL, Salvesen O, Selle H. et al Short-term continuous glucose monitoring: effects on glucose and treatment satisfaction in patients with type 1 diabetes mellitus; a randomized controlled trial.. Int J Clin Pract 2012; 66: 741-747 doi: 10.1111/j.1742-1241.2012.02947.x
• 13 Little SA, Leelarathna L, Walkinshaw E. et al Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).. Diabetes Care 2014; 37: 2114-2122 doi: 10.2337/dc14-003
• 14 Tumminia A, Crimi S, Sciacca L. et al Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial.. Diabetes Metab Res Rev 2015; 31: 61-68 doi: 10.1002/dmrr.2557
• 15 Polonsky WH, Hessler D, Ruedy KJ. et al The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial.. Diabetes Care 2017; 40: 736-741 doi: 10.2337/dc17-0133
• 16 Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: an effective, less-expensive option.. JAMA 2017; 318: 23-24 doi:10.1001/jama.2017.6939